RecruitingPhase 1

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

China48 participantsStarted 2024-05-31

Plain-language summary

This study examines the safety, tolerability and preliminary efficacy of anti-CD19 /CD22 CAR T cells (KQ-2002)manufactured on-site in adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin lymphoma.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Second or greater relapse (CD20 regimens must be included) OR
✓. Refractory to first-line chemotherapy or relapse within 1 year OR
✓. Relapse within 1 year of auto-HSCT.
✓. With measurable or evaluable lesions（Dose expansion cohort） (B-ALL)

What they're measuring

Incidence of Dose-limiting toxicity

Timeframe: Up to 28 days

Incidence and severity of adverse events

Timeframe: Up to 15 years

Trial details

NCT IDNCT06445803

SponsorRong Tao

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-10

Contact for this trial

Weijing Zhang

021-64175590 JJYIN555@163.com

View on ClinicalTrials.gov More Acute Lymphoblastic Leukemia, in Relapse trials